Inoviem Scientific Advances Drug Development with Patient-Centric Approach

Aton Group has provided an update on its subsidiary, Inoviem Scientific, emphasizing its innovative approach in drug development. Inoviem Scientific places patient samples at the heart of all development stages, from research to clinical practice.

The company integrates technologies for analyzing patient-derived samples with AI molecular characterization. This platform aids drug development from R&D to clinical decision-making, promoting personalized medicine over conventional models.

Two preclinical programs illustrate this model, allowing rapid functional analysis of drug candidates using patient samples. This approach offers biopharmaceutical partners essential translational data, potentially reducing timelines and costs.

Inoviem Scientific is solidifying its role as a strategic partner in early-stage drug discovery, highlighting its operational capabilities to meet growing demand for predictive preclinical models.